Serina Therapeutics, Inc. (SER) — 8-K Filings

8-K Filings (44)

• 8-K Filing — Apr 21, 2026
• Serina Therapeutics Files 8-K — Dec 10, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on December 10, 2025, reporting other events and financial statements. The company, formerly known as AgeX Therapeutics,
• Serina Therapeutics Files 8-K on Shareholder Votes and Financials — Nov 12, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on November 12, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing a
• 8-K Filing — Nov 3, 2025
• Serina Therapeutics Files 8-K — Oct 6, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as AgeX Therapeutics, In
• Serina Therapeutics Enters Material Agreement, Reports Equity Sales — Sep 15, 2025 Risk: medium
  Serina Therapeutics, Inc. announced on September 9, 2025, that it entered into a material definitive agreement. The company also reported the creation of a dire
• Serina Therapeutics Files 8-K — Sep 9, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on September 9, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly k
• Serina Therapeutics Files 8-K — Aug 25, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on August 25, 2025, reporting other events and financial statements/exhibits. The company, formerly known as AgeX Therape
• Serina Therapeutics Files 8-K with Corporate Updates — Aug 22, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on August 22, 2025, reporting events as of August 18, 2025. The filing includes amendments to its articles of incorporati
• Serina Therapeutics Files 8-K — Jul 29, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on July 29, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Serina Therapeutics Files 8-K on Shareholder Nominations — Jul 1, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on July 1, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11, Regulation FD disclosure, and
• Serina Therapeutics Files 8-K: Officer/Director Changes & More — May 22, 2025 Risk: medium
  Serina Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting on several key events. These include the departure of directors or certain officers, the elect
• Serina Therapeutics Files 8-K, Reports Material Agreement — Apr 29, 2025 Risk: medium
  On April 25, 2025, Serina Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
• Serina Therapeutics Files 8-K — Apr 15, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on April 15, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Serina Therapeutics Announces Material Definitive Agreement — Apr 14, 2025 Risk: medium
  Serina Therapeutics, Inc. announced on April 8, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equ
• Serina Therapeutics Files 8-K — Apr 7, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on April 7, 2025, to report information under Regulation FD and to file financial statements and exhibits. The company, f
• Serina Therapeutics Announces Director Departure and Officer Appointments — Feb 12, 2025 Risk: medium
  Serina Therapeutics, Inc. announced on February 11, 2025, the departure of Director Dr. David E. Bearss and the election of Dr. Robert E. T. Smith as a new dire
• Serina Therapeutics Files 8-K — Feb 3, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on February 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
• Serina Therapeutics Announces Board and Executive Changes — Jan 15, 2025 Risk: medium
  Serina Therapeutics, Inc. announced on January 14, 2025, changes related to its board of directors and executive compensation. The filing details the departure
• Serina Therapeutics Files 8-K on Financials — Jan 6, 2025 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
• Serina Therapeutics Files 8-K on Definitive Agreement & Asset Deal — Dec 26, 2024 Risk: medium
  Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.) filed an 8-K on December 26, 2024, reporting on events that occurred on December 23, 2024. The fili
• Serina Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes — Dec 18, 2024 Risk: medium
  Serina Therapeutics, Inc. filed an 8-K on December 18, 2024, reporting on events that occurred on December 13, 2024. The filing indicates changes related to the
• Serina Therapeutics Files 8-K — Dec 11, 2024 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on December 11, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Serina Therapeutics Files 8-K: Material Agreement & Equity Sales — Dec 2, 2024 Risk: medium
  Serina Therapeutics, Inc. announced on November 26, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales
• Serina Therapeutics Files 8-K on Financials — Nov 12, 2024 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, and including financial statements
• Serina Therapeutics Files 8-K — Oct 2, 2024 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on October 2, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
• Serina Therapeutics: Director Departs, CMO Appointed — Sep 12, 2024 Risk: medium
  Serina Therapeutics, Inc. announced on September 8, 2024, the departure of Director Dr. David E. Smith and the appointment of Dr. David E. Smith as Chief Medica
• Serina Therapeutics Files 8-K with Regulatory Updates — Sep 5, 2024 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on September 5, 2024, reporting events as of September 4, 2024. The filing is primarily a Regulation FD Disclosure and in
• Serina Therapeutics Announces Board and Executive Changes — Aug 16, 2024 Risk: medium
  Serina Therapeutics, Inc. announced on August 12, 2024, a change in its board of directors and executive compensation arrangements. The filing details the depar
• Serina Therapeutics Files 8-K — Jul 29, 2024 Risk: low
  Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.) filed an 8-K on July 29, 2024, reporting on financial statements and exhibits. The company, incorpo
• Serina Therapeutics Appoints New CMO, Director — Jul 18, 2024 Risk: low
  Serina Therapeutics, Inc. announced on July 15, 2024, the appointment of Dr. David E. Smith as Chief Medical Officer and the election of Ms. Sarah E. Johnson to
• Serina Therapeutics Appoints New CMO, Director — Jul 12, 2024 Risk: medium
  Serina Therapeutics, Inc. announced on July 9, 2024, the appointment of Dr. David E. Johnson as Chief Medical Officer and the election of Ms. Jennifer L. Johnso
• Serina Therapeutics Files 8-K for Other Event — Jun 10, 2024 Risk: medium
  Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.) filed an 8-K on June 10, 2024, reporting an "Other Event" that occurred on June 6, 2024. The filing
• Serina Therapeutics Files 8-K on Financials — May 14, 2024 Risk: low
  Serina Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, and including financial statements and e
• Serina Therapeutics Changes Principal Accounting Firm — May 3, 2024 Risk: low
  Serina Therapeutics, Inc. announced on April 29, 2024, a change in its principal accounting firm. The company's former independent registered public accounting
• Serina Therapeutics Appoints New Directors, CEO Compensation Change — Apr 17, 2024 Risk: medium
  Serina Therapeutics, Inc. announced on April 12, 2024, a change in its board of directors. Specifically, Dr. David E. R. Sutherland was appointed as a Class II
• AgeX Therapeutics Acquired by 03 Life Sciences — Apr 1, 2024 Risk: medium
  AgeX Therapeutics, Inc. announced on March 26, 2024, the completion of its acquisition by 03 Life Sciences. The transaction involved the issuance of 1,000,000 s
• AgeX Therapeutics Files 8-K: Stockholder Meeting, Bylaw Changes — Mar 14, 2024 Risk: medium
  On March 14, 2024, AgeX Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockhol
• AgeX Therapeutics Secures Up to $20M Loan — Mar 7, 2024 Risk: medium
  On March 5, 2024, AgeX Therapeutics, Inc. entered into a loan agreement with Oxford Finance LLC for up to $20 million. The initial draw was $5 million, with the
• AgeX Therapeutics Enters Material Agreement, New Financial Obligation — Feb 14, 2024 Risk: medium
  AgeX Therapeutics, Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 9, 2024. The filing indicates the pharmaceutical prepara
• AgeX Therapeutics Reports Merger-Related Financial Obligations, Equity Sales — Feb 6, 2024
  AgeX Therapeutics, Inc. filed an 8-K on February 6, 2024, reporting events from February 1, 2024, related to its ongoing merger with Serina Therapeutics, Inc. T
• AgeX Therapeutics Reports New Direct Financial Obligation — Jan 19, 2024
  AgeX Therapeutics, Inc. (AGE) filed an 8-K on January 19, 2024, reporting a new direct financial obligation that occurred on January 16, 2024. This filing indic
• AgeX Therapeutics Reports Executive/Director Changes, Comp. Arrangements — Jan 11, 2024
  AgeX Therapeutics, Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 8, 2024. This filing indicates a change in the company's e
• AgeX Therapeutics Reports New Direct Financial Obligation — Jan 5, 2024
  AgeX Therapeutics, Inc. filed an 8-K on January 5, 2024, reporting a direct financial obligation created on January 3, 2024. This filing indicates a new financi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX